Abzena and Mabqi have announced a partnership integrating antibody discovery capabilities with development and manufacturing services for a drug development solution.
Through this integration, the collaboration aims to provide biopharma customers with an end-to-end, streamlined solution that bridges discovery through selection of lead candidates into pre-clinical development and beyond.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The partnership also addresses early-stage development challenges by combining accelerated development timelines, scientific and technical support, and streamlined workflows.
Its integrated services will utilise Mabqi’s LiteMab antibody discovery studio for hit selection, screening and characterisation by employing pH-sensitive and universal libraries to identify top lead candidates.
The offerings will also leverage Abzena’s expertise in GMP manufacturing, cell line development, developability, and process development.
Both organisations support a broad range of modalities, including bioconjugates, bi and multi-specifics, monoclonal antibodies (mAbs) and mAb fragments.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAbzena chief scientific officer Campbell Bunce stated: “Our partnership with Mabqi brings together two science-rich organisations that are focused on advancing antibody innovation through integration.
“The combination of our capabilities enables us to significantly accelerate our customers’ discovery programmes from end-to-end by leveraging data to streamline and de-risk earlier on in development, enabling a faster and more successful path to the clinic.”
Mabqi CEO Sylvain Yon said: “Our strategic partnership with Abzena marks a significant milestone in offering an integrated antibody discovery-through-development solution by combining our complementary scientific expertise and advanced capabilities.
“Beyond scientific excellence and innovation, what truly sets this collaboration apart is the exceptional human fit between our teams ensuring smooth cooperation, shared dedication to innovation and customer-focused relationship.”
The companies together aim to expedite differentiated therapeutic antibodies development for patients globally.
